| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
TScan Therapeutics Inc. Common Stock (NASDAQ: TCRX)
TCRX Technical Analysis
4
| As on 9th Jun 2023 TCRX STOCK Price closed @ 2.91 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.40 & Strong Sell for SHORT-TERM with Stoploss of 4.69 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TCRXSTOCK Price
| Open | 3.11 | Change | Price | % |
| High | 3.21 | 1 Day | -0.20 | -6.43 |
| Low | 2.77 | 1 Week | 0.61 | 26.52 |
| Close | 2.91 | 1 Month | 0.72 | 32.88 |
| Volume | 204800 | 1 Year | -1.95 | -40.12 |
| 52 Week High 5.40 | 52 Week Low 1.49 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| TCRX Daily Charts |
TCRX Intraday Charts |
Whats New @ Bazaartrend |
TCRX Free Analysis |
|
|
TCRX Important Levels Intraday
| RESISTANCE | 3.76 |
| RESISTANCE | 3.49 |
| RESISTANCE | 3.32 |
| RESISTANCE | 3.15 |
| SUPPORT | 2.67 |
| SUPPORT | 2.50 |
| SUPPORT | 2.33 |
| SUPPORT | 2.06 |
TCRX Forecast May 2024
| 4th UP Forecast | 5.63 |
| 3rd UP Forecast | 4.76 |
| 2nd UP Forecast | 4.22 |
| 1st UP Forecast | 3.68 |
| 1st DOWN Forecast | 2.14 |
| 2nd DOWN Forecast | 1.6 |
| 3rd DOWN Forecast | 1.06 |
| 4th DOWN Forecast | 0.19 |
TCRX Weekly Forecast
| 4th UP Forecast | 4.74 |
| 3rd UP Forecast | 4.15 |
| 2nd UP Forecast | 3.79 |
| 1st UP Forecast | 3.43 |
| 1st DOWN Forecast | 2.39 |
| 2nd DOWN Forecast | 2.03 |
| 3rd DOWN Forecast | 1.67 |
| 4th DOWN Forecast | 1.08 |
TCRX Forecast2024
| 4th UP Forecast | 11.74 |
| 3rd UP Forecast | 8.91 |
| 2nd UP Forecast | 7.16 |
| 1st UP Forecast | 5.41 |
| 1st DOWN Forecast | 0.41 |
| 2nd DOWN Forecast | -1.34 |
| 3rd DOWN Forecast | -3.09 |
| 4th DOWN Forecast | -5.92 |
TScan Therapeutics Inc. Common Stock ( NASDAQ USA Symbol : TCRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TCRX Business Profile
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Address: 830 Winter Street, Waltham, MA, United States, 02451
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service